Urica Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Bay Harbor Islands, Florida, United States
Type:
sample
Technology:
sample
About: Urica Therapeutics, Inc. (“Urica”) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. Urica acquired the rights to develop and commercialize Dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union, Canada, Middle East and North Africa (MENA) and Turkey from Fuji Yakuhin. Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase 1 clinical trial in the United States. Urica was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Urica Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.